282 related articles for article (PubMed ID: 30219580)
1. Phase IIa trial in Duchenne muscular dystrophy shows vamorolone is a first-in-class dissociative steroidal anti-inflammatory drug.
Conklin LS; Damsker JM; Hoffman EP; Jusko WJ; Mavroudis PD; Schwartz BD; Mengle-Gaw LJ; Smith EC; Mah JK; Guglieri M; Nevo Y; Kuntz N; McDonald CM; Tulinius M; Ryan MM; Webster R; Castro D; Finkel RS; Smith AL; Morgenroth LP; Arrieta A; Shimony M; Jaros M; Shale P; McCall JM; Hathout Y; Nagaraju K; van den Anker J; Ward LM; Ahmet A; Cornish MR; Clemens PR
Pharmacol Res; 2018 Oct; 136():140-150. PubMed ID: 30219580
[TBL] [Abstract][Full Text] [Related]
2. Vamorolone trial in Duchenne muscular dystrophy shows dose-related improvement of muscle function.
Hoffman EP; Schwartz BD; Mengle-Gaw LJ; Smith EC; Castro D; Mah JK; McDonald CM; Kuntz NL; Finkel RS; Guglieri M; Bushby K; Tulinius M; Nevo Y; Ryan MM; Webster R; Smith AL; Morgenroth LP; Arrieta A; Shimony M; Siener C; Jaros M; Shale P; McCall JM; Nagaraju K; van den Anker J; Conklin LS; Cnaan A; Gordish-Dressman H; Damsker JM; Clemens PR;
Neurology; 2019 Sep; 93(13):e1312-e1323. PubMed ID: 31451516
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and Safety of Vamorolone in Duchenne Muscular Dystrophy: A 30-Month Nonrandomized Controlled Open-Label Extension Trial.
Mah JK; Clemens PR; Guglieri M; Smith EC; Finkel RS; Tulinius M; Nevo Y; Ryan MM; Webster R; Castro D; Kuntz NL; McDonald CM; Damsker JM; Schwartz BD; Mengle-Gaw LJ; Jackowski S; Stimpson G; Ridout DA; Ayyar-Gupta V; Baranello G; Manzur AY; Muntoni F; Gordish-Dressman H; Leinonen M; Ward LM; Hoffman EP; Dang UJ;
JAMA Netw Open; 2022 Jan; 5(1):e2144178. PubMed ID: 35076703
[TBL] [Abstract][Full Text] [Related]
4. Exposure-Response Analysis of Vamorolone (VBP15) in Boys With Duchenne Muscular Dystrophy.
Li X; Conklin LS; van den Anker J; Hoffman EP; Clemens PR; Jusko WJ
J Clin Pharmacol; 2020 Oct; 60(10):1385-1396. PubMed ID: 32434278
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of vamorolone in Duchenne muscular dystrophy: An 18-month interim analysis of a non-randomized open-label extension study.
Smith EC; Conklin LS; Hoffman EP; Clemens PR; Mah JK; Finkel RS; Guglieri M; Tulinius M; Nevo Y; Ryan MM; Webster R; Castro D; Kuntz NL; Kerchner L; Morgenroth LP; Arrieta A; Shimony M; Jaros M; Shale P; Gordish-Dressman H; Hagerty L; Dang UJ; Damsker JM; Schwartz BD; Mengle-Gaw LJ; McDonald CM;
PLoS Med; 2020 Sep; 17(9):e1003222. PubMed ID: 32956407
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and Safety of Vamorolone vs Placebo and Prednisone Among Boys With Duchenne Muscular Dystrophy: A Randomized Clinical Trial.
Guglieri M; Clemens PR; Perlman SJ; Smith EC; Horrocks I; Finkel RS; Mah JK; Deconinck N; Goemans N; Haberlova J; Straub V; Mengle-Gaw LJ; Schwartz BD; Harper AD; Shieh PB; De Waele L; Castro D; Yang ML; Ryan MM; McDonald CM; Tulinius M; Webster R; McMillan HJ; Kuntz NL; Rao VK; Baranello G; Spinty S; Childs AM; Sbrocchi AM; Selby KA; Monduy M; Nevo Y; Vilchez-Padilla JJ; Nascimento-Osorio A; Niks EH; de Groot IJM; Katsalouli M; James MK; van den Anker J; Damsker JM; Ahmet A; Ward LM; Jaros M; Shale P; Dang UJ; Hoffman EP
JAMA Neurol; 2022 Oct; 79(10):1005-1014. PubMed ID: 36036925
[TBL] [Abstract][Full Text] [Related]
7. Considering the Promise of Vamorolone for Treating Duchenne Muscular Dystrophy.
Grounds MD; Lloyd EM
J Neuromuscul Dis; 2023; 10(6):1013-1030. PubMed ID: 37927274
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and Safety of Vamorolone Over 48 Weeks in Boys With Duchenne Muscular Dystrophy: A Randomized Controlled Trial.
Dang UJ; Damsker JM; Guglieri M; Clemens PR; Perlman SJ; Smith EC; Horrocks I; Finkel RS; Mah JK; Deconinck N; Goemans NM; Haberlová J; Straub V; Mengle-Gaw L; Schwartz BD; Harper A; Shieh PB; De Waele L; Castro D; Yang ML; Ryan MM; McDonald CM; Tulinius M; Webster RI; Mcmillan HJ; Kuntz N; Rao VK; Baranello G; Spinty S; Childs AM; Sbrocchi AM; Selby KA; Monduy M; Nevo Y; Vilchez JJ; Nascimento-Osorio A; Niks EH; De Groot IJM; Katsalouli M; Van Den Anker JN; Ward LM; Leinonen M; D'Alessandro AL; Hoffman EP
Neurology; 2024 Mar; 102(5):e208112. PubMed ID: 38335499
[TBL] [Abstract][Full Text] [Related]
9. Population Pharmacokinetics of Vamorolone (VBP15) in Healthy Men and Boys With Duchenne Muscular Dystrophy.
Mavroudis PD; van den Anker J; Conklin LS; Damsker JM; Hoffman EP; Nagaraju K; Clemens PR; Jusko WJ
J Clin Pharmacol; 2019 Jul; 59(7):979-988. PubMed ID: 30742306
[TBL] [Abstract][Full Text] [Related]
10. Phase 1 trial of vamorolone, a first-in-class steroid, shows improvements in side effects via biomarkers bridged to clinical outcomes.
Hoffman EP; Riddle V; Siegler MA; Dickerson D; Backonja M; Kramer WG; Nagaraju K; Gordish-Dressman H; Damsker JM; McCall JM
Steroids; 2018 Jun; 134():43-52. PubMed ID: 29524454
[TBL] [Abstract][Full Text] [Related]
11. Vamorolone targets dual nuclear receptors to treat inflammation and dystrophic cardiomyopathy.
Heier CR; Yu Q; Fiorillo AA; Tully CB; Tucker A; Mazala DA; Uaesoontrachoon K; Srinivassane S; Damsker JM; Hoffman EP; Nagaraju K; Spurney CF
Life Sci Alliance; 2019 Feb; 2(1):. PubMed ID: 30745312
[TBL] [Abstract][Full Text] [Related]
12. Muscle miRNAome shows suppression of chronic inflammatory miRNAs with both prednisone and vamorolone.
Fiorillo AA; Tully CB; Damsker JM; Nagaraju K; Hoffman EP; Heier CR
Physiol Genomics; 2018 Sep; 50(9):735-745. PubMed ID: 29883261
[TBL] [Abstract][Full Text] [Related]
13. Disruption of a key ligand-H-bond network drives dissociative properties in vamorolone for Duchenne muscular dystrophy treatment.
Liu X; Wang Y; Gutierrez JS; Damsker JM; Nagaraju K; Hoffman EP; Ortlund EA
Proc Natl Acad Sci U S A; 2020 Sep; 117(39):24285-24293. PubMed ID: 32917814
[TBL] [Abstract][Full Text] [Related]
14. Vamorolone: First Approval.
Keam SJ
Drugs; 2024 Jan; 84(1):111-117. PubMed ID: 38103149
[TBL] [Abstract][Full Text] [Related]
15. Biomarker-focused multi-drug combination therapy and repurposing trial in mdx mice.
Ziemba M; Barkhouse M; Uaesoontrachoon K; Giri M; Hathout Y; Dang UJ; Gordish-Dressman H; Nagaraju K; Hoffman EP
PLoS One; 2021; 16(2):e0246507. PubMed ID: 33617542
[TBL] [Abstract][Full Text] [Related]
16. Comparison of pharmaceutical properties and biological activities of prednisolone, deflazacort, and vamorolone in DMD disease models.
Liu G; Lipari P; Mollin A; Jung S; Teplova I; Li W; Ying L; More V; Lennox W; Yeh S; McGann E; Moon YC; Rice C; Huarte E; Gruszka B; Ray B; Goodwin E; Buckendahl P; Yurkow E; Braughton B; Narasimhan J; Welch E; Voronin G; Weetall M
Hum Mol Genet; 2024 Jan; 33(3):211-223. PubMed ID: 37819629
[TBL] [Abstract][Full Text] [Related]
17. Assessing Pharmacogenomic loci Associated with the Pharmacokinetics of Vamorolone in Boys with Duchenne Muscular Dystrophy.
Li X; Sabbatini D; Pegoraro E; Bello L; Clemens P; Guglieri M; van den Anker J; Damsker J; McCall J; Dang UJ; Hoffman EP; Jusko WJ
J Clin Pharmacol; 2024 Apr; ():. PubMed ID: 38682893
[TBL] [Abstract][Full Text] [Related]
18. Rimeporide as a first- in-class NHE-1 inhibitor: Results of a phase Ib trial in young patients with Duchenne Muscular Dystrophy.
Previtali SC; Gidaro T; Díaz-Manera J; Zambon A; Carnesecchi S; Roux-Lombard P; Spitali P; Signorelli M; Szigyarto CA; Johansson C; Gray J; Labolle D; Porte Thomé F; Pitchforth J; Domingos J; Muntoni F
Pharmacol Res; 2020 Sep; 159():104999. PubMed ID: 32535224
[TBL] [Abstract][Full Text] [Related]
19. Vamorolone, a dissociative steroidal compound, reduces collagen antibody-induced joint damage and inflammation when administered after disease onset.
Damsker JM; Cornish MR; Kanneboyina P; Kanneboyina I; Yu Q; Lipson R; Phadke A; Knoblach SM; Panchapakesan K; Morales M; Fiorillo AA; Partridge T; Nagaraju K
Inflamm Res; 2019 Nov; 68(11):969-980. PubMed ID: 31446438
[TBL] [Abstract][Full Text] [Related]
20. Serum pharmacodynamic biomarkers for chronic corticosteroid treatment of children.
Hathout Y; Conklin LS; Seol H; Gordish-Dressman H; Brown KJ; Morgenroth LP; Nagaraju K; Heier CR; Damsker JM; van den Anker JN; Henricson E; Clemens PR; Mah JK; McDonald C; Hoffman EP
Sci Rep; 2016 Aug; 6():31727. PubMed ID: 27530235
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
